RS62916B1 - Čvrste oralne kompozicije sa sporim oslobađanjem - Google Patents

Čvrste oralne kompozicije sa sporim oslobađanjem

Info

Publication number
RS62916B1
RS62916B1 RS20220156A RSP20220156A RS62916B1 RS 62916 B1 RS62916 B1 RS 62916B1 RS 20220156 A RS20220156 A RS 20220156A RS P20220156 A RSP20220156 A RS P20220156A RS 62916 B1 RS62916 B1 RS 62916B1
Authority
RS
Serbia
Prior art keywords
pharmaceutically acceptable
composition
salt
acceptable salt
shellac
Prior art date
Application number
RS20220156A
Other languages
English (en)
Serbian (sr)
Inventor
Daniele Giovannone
Niccolò MIRAGLIA
Marco Berna
Original Assignee
Gnosis Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gnosis Spa filed Critical Gnosis Spa
Publication of RS62916B1 publication Critical patent/RS62916B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/20—Agglomerating; Granulating; Tabletting
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20220156A 2013-11-18 2014-11-06 Čvrste oralne kompozicije sa sporim oslobađanjem RS62916B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT001906A ITMI20131906A1 (it) 2013-11-18 2013-11-18 Composizioni solide orali a lento rilascio
US201461989645P 2014-05-07 2014-05-07
EP14812619.6A EP3071191B1 (en) 2013-11-18 2014-11-06 Slow-release solid oral compositions
PCT/IB2014/065852 WO2015071806A1 (en) 2013-11-18 2014-11-06 Slow-release solid oral compositions

Publications (1)

Publication Number Publication Date
RS62916B1 true RS62916B1 (sr) 2022-03-31

Family

ID=49780196

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220156A RS62916B1 (sr) 2013-11-18 2014-11-06 Čvrste oralne kompozicije sa sporim oslobađanjem

Country Status (26)

Country Link
US (1) US10702482B2 (enExample)
EP (1) EP3071191B1 (enExample)
JP (1) JP6401270B2 (enExample)
KR (1) KR102224087B1 (enExample)
CN (1) CN105764493B (enExample)
AU (1) AU2014349782B2 (enExample)
BR (1) BR112016011142B1 (enExample)
CA (1) CA2929426C (enExample)
DK (1) DK3071191T3 (enExample)
EA (1) EA039558B1 (enExample)
ES (1) ES2908924T3 (enExample)
GE (1) GEP20186884B (enExample)
HR (1) HRP20220271T1 (enExample)
HU (1) HUE058086T2 (enExample)
IL (1) IL245167B (enExample)
IT (1) ITMI20131906A1 (enExample)
LT (1) LT3071191T (enExample)
MX (1) MX367664B (enExample)
NZ (1) NZ719000A (enExample)
PH (1) PH12016500693A1 (enExample)
PL (1) PL3071191T3 (enExample)
PT (1) PT3071191T (enExample)
RS (1) RS62916B1 (enExample)
UA (1) UA119856C2 (enExample)
WO (1) WO2015071806A1 (enExample)
ZA (1) ZA201602659B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700074957A1 (it) * 2017-07-04 2019-01-04 Gnosis Spa Sale di (ss)-adenosil metionina con inositolo esafosfato e procedimento per ottenerlo
CN109939077B (zh) * 2017-12-04 2022-07-22 深圳奥萨制药有限公司 一种含有5-甲基四氢叶酸的控释制剂
CN111990674B (zh) * 2020-01-14 2021-07-02 青岛圣邦健康食品有限公司 肠溶包衣材料及其制备方法和肠溶制品
IT202000006127A1 (it) * 2020-03-23 2021-09-23 Fmc S R L Formulazione farmaceutica, dietetica e/o alimentare a base ademetionina e processo di realizzazione di detta formulazione
IT202300007692A1 (it) * 2023-04-19 2024-10-19 Vifra S R L Formulazione farmaceutica, dietetica e/o alimentare a base ademetionina e processo di realizzazione di detta formulazione

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1200589B (it) * 1985-02-14 1989-01-27 Gibipharma Spa Derivati naturali attivita farmagologica
ITMI20012462A1 (it) * 2001-11-22 2003-05-22 Gnosis Srl Processo per la preparazione di compresse comprendenti s-adenosilmetionina
US20050181047A1 (en) * 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements
JP2008519071A (ja) 2004-11-05 2008-06-05 ファーブル−クレイマー・ホールディングス・インコーポレイテッド ゲピロンの高用量徐放性製剤
ITMI20060629A1 (it) * 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
US20090088404A1 (en) 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
KR20070093972A (ko) * 2007-06-05 2007-09-19 파브르-크래머 홀딩스. 인크 게피론의 고용량 서방성 제제
US7947662B2 (en) * 2008-02-20 2011-05-24 Gnosis S.P.A. Folates, compositions and uses thereof
US20110027342A1 (en) 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
IT1401146B1 (it) * 2010-07-27 2013-07-12 Gnosis Spa Composizione comprendente shellac e/o un suo sale e sodio amido glicolato

Also Published As

Publication number Publication date
EA039558B1 (ru) 2022-02-10
UA119856C2 (uk) 2019-08-27
CA2929426C (en) 2021-08-31
PL3071191T3 (pl) 2022-04-04
DK3071191T3 (da) 2022-03-07
WO2015071806A1 (en) 2015-05-21
ITMI20131906A1 (it) 2015-05-19
HRP20220271T1 (hr) 2022-05-13
LT3071191T (lt) 2022-04-25
ZA201602659B (en) 2017-08-30
JP2016539112A (ja) 2016-12-15
IL245167A0 (en) 2016-06-30
PH12016500693B1 (en) 2016-05-30
CN105764493A (zh) 2016-07-13
CA2929426A1 (en) 2015-05-21
ES2908924T3 (es) 2022-05-04
PT3071191T (pt) 2022-04-05
JP6401270B2 (ja) 2018-10-10
EP3071191B1 (en) 2022-01-05
NZ719000A (en) 2017-06-30
GEP20186884B (en) 2018-07-25
BR112016011142A2 (enExample) 2017-08-08
BR112016011142B1 (pt) 2023-01-03
EP3071191A1 (en) 2016-09-28
CN105764493B (zh) 2020-02-21
US10702482B2 (en) 2020-07-07
KR102224087B1 (ko) 2021-03-10
KR20160086829A (ko) 2016-07-20
MX367664B (es) 2019-08-30
MX2016006442A (es) 2016-12-09
HUE058086T2 (hu) 2022-07-28
US20160287519A1 (en) 2016-10-06
IL245167B (en) 2020-04-30
PH12016500693A1 (en) 2016-05-30
EA201691034A1 (ru) 2016-09-30
AU2014349782B2 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
Darji et al. Excipient stability in oral solid dosage forms: a review
JP7148498B2 (ja) （ｒ）－２－アミノ－３－フェニルプロピルカルバメートの製剤
RS62916B1 (sr) Čvrste oralne kompozicije sa sporim oslobađanjem
JP2006519849A (ja) 放出制御トラマドールの漸増投薬処方
TW200413006A (en) Solid dispersions comprising a hygroscopic and/or deliquescent drug
ES2650368T3 (es) Composiciones y procedimientos para superar la resistencia al tramadol
TW201630593A (zh) 特別用於治療注意力缺失症之方法及組成物
TWI798488B (zh) 環絲胺酸化合物的製劑及其應用
CN103919715A (zh) 含有甘磷酸胆碱或其盐的控释药物组合物及其制备方法
AU2006341243B2 (en) Solid oral compositions based on S-adenosyl methionine and/or NADH and process for obtaining them
AU2014349782A1 (en) Slow-release solid oral compositions
RS63383B1 (sr) Sastavi prijatnog ukusa koji uključuju natrijum fenilbutirat i njihova primena
RS64158B1 (sr) Formulacija afabicina, postupak za njenu proizvodnju
WO2015017423A2 (en) Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture
CA2847328A1 (en) Oral formulations containing hyaluronic acid for sustained drug release
EP1971370B1 (en) Oral s-adenosylmethionine compositions
RS54305B1 (sr) Kompozicija koja uključuje šelak i/ili njegovu so i natrijum skrob glikolat
CN121311219A (zh) 不含二氧化钛的琥珀酸多西拉敏和盐酸吡哆醇的多单位口服剂型
JP2020055837A (ja) 多発性硬化症の治療のための組成物及び方法